Absci Expects Cash To Fund Operations Into 2028 As It Builds A Commercial Team

The AI drug developer expects hair-regrowth results in December and appointed a former Galderma executive as commercial chief.

Share
Absci Expects Cash To Fund Operations Into 2028 As It Builds A Commercial Team

Absci, which is testing an AI-designed antibody for hair loss, expects its $173.7 million in cash and securities to fund operations into the second half of 2028. Its Thursday SEC filing accompanied results and a commercial-team appointment as the company prepares for hair-regrowth data anticipated in December.

Commercial Planning Before Hair-Regrowth Results

Absci held $173.7 million in cash, cash equivalents and marketable securities at September 30, down from $201.1 million at June 30. The company's funding estimate rests on its current operating projections.

The company appointed Gerry Muhle, a former Galderma executive, chief commercial officer. Muhle has more than 25 years of experience in pharmaceutical, aesthetics and consumer businesses.

Sean McClain, Absci's founder and CEO, said, “As ABS-201 progresses through the clinic, we have begun building our commercial infrastructure to support this and potential future programs.”

Absci designs antibody drug candidates with AI, then tests the molecules in laboratories. It develops its own medicines and works on drug discovery with partners including Merck, AstraZeneca and Almirall. Those collaborations can generate upfront fees, research payments, milestones and royalties.

ABS-201's Next Clinical Tests

Absci anticipates interim hair-regrowth results at 13 weeks in December 2026, followed by full 26-week results early in 2027. Participants are continuing to receive treatment in the multiple-dose portion of the hair-loss trial.

In June, Absci reported that the study medication appeared well tolerated in the blinded single-dose groups. The company said an estimated half-life of at least 65 days supported its proposed schedule of two or three injections over six months. Half-life measures how long it takes the amount of a drug in the body to fall by half.

Absci also expects to begin a mid-stage trial of ABS-201 for endometriosis in mid-2027. The planned study would compare the drug with a placebo in participants with surgically diagnosed endometriosis and moderate to severe associated pain.

The company anticipates approximately 150 participants across approximately 10 or more countries, pending a final protocol and regulatory clearance. It plans to test two or three dose levels, with the choices informed by the hair-loss study. Measures would include patient-reported changes in menstrual pain and pelvic pain outside menstruation.

ABS-201 Development Raises Research Costs

Third-quarter research spending increased to $23.6 million from $19.2 million a year earlier. Absci attributed the increase mainly to progress in its internal programs, including external preclinical and clinical work on ABS-201; lower personnel costs partly offset the increase.

Selling and administrative expenses rose to $9.0 million from $8.4 million, primarily because of stock-based pay, according to Absci. Revenue from partner programs declined to $0.3 million from $0.4 million.

The quarterly net loss widened to $33.3 million from $28.7 million. Loss per share narrowed to $0.19 from $0.20, with weighted-average shares outstanding rising to 171,799,223 from 143,769,552.

December's planned readout will assess hair regrowth, adding efficacy findings to the safety and dosing evidence Absci reported in June.

Sources